Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy.

Tran TT, Mahajan A, Chiang VL, Goldberg SB, Nguyen DX, Jilaveanu LB, Kluger HM.

J Immunother Cancer. 2019 Jul 30;7(1):200. doi: 10.1186/s40425-019-0684-z.

2.

Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab.

Hamid O, Molinero L, Bolen CR, Sosman JA, Muñoz-Couselo E, Kluger HM, McDermott DF, Powderly J, Sarkar I, Ballinger M, Fassò M, O'Hear C, Chen DS, Hegde PS, Hodi FS.

Clin Cancer Res. 2019 Jul 29. pii: clincanres.3488.2018. doi: 10.1158/1078-0432.CCR-18-3488. [Epub ahead of print]

PMID:
31358540
3.

Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.

Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C.

J Immunother Cancer. 2019 Jul 24;7(1):196. doi: 10.1186/s40425-019-0672-3.

4.

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.

Wong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, Rimm DL.

J Immunother Cancer. 2019 Jul 23;7(1):194. doi: 10.1186/s40425-019-0675-0.

5.

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.

Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM.

J Immunother Cancer. 2019 Jun 14;7(1):153. doi: 10.1186/s40425-019-0613-1.

6.

High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.

Toki MI, Merritt CR, Wong PF, Smithy JW, Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM, Rimm DL.

Clin Cancer Res. 2019 Jun 12. doi: 10.1158/1078-0432.CCR-19-0104. [Epub ahead of print]

PMID:
31189645
7.

Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis.

Wingrove E, Liu ZZ, Patel KD, Arnal-Estapé A, Cai WL, Melnick MA, Politi K, Monteiro C, Zhu L, Valiente M, Kluger HM, Chiang VL, Nguyen DX.

Cell Rep. 2019 Apr 23;27(4):1277-1292.e7. doi: 10.1016/j.celrep.2019.03.085.

8.

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.

Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A.

Cancer Discov. 2019 Jun;9(6):711-721. doi: 10.1158/2159-8290.CD-18-1495. Epub 2019 Apr 15.

PMID:
30988166
9.

Reply to A. Shinde et al.

Kluger HM, Margolin KA, Davies MA, Long GV, Tawbi HA, Goldberg SB, Chiang VL.

J Clin Oncol. 2019 Apr 20;37(12):1031-1032. doi: 10.1200/JCO.18.02463. Epub 2019 Feb 26. No abstract available.

PMID:
30807233
10.

Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series.

Kim JM, Materin MA, Sznol M, Kluger HM, Weiss S, Chow J, Stoessel K, Kombo N, Del Priore L, Pointdujour-Lim R.

Ophthalmology. 2019 Jul;126(7):1058-1062. doi: 10.1016/j.ophtha.2019.01.031. Epub 2019 Feb 6. No abstract available.

PMID:
30735682
11.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL.

J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6.

PMID:
30726175
12.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM.

Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19.

PMID:
30712316
13.

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.

Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KRM, Zelterman D, Kluger HM, Rimm DL.

Clin Cancer Res. 2019 Apr 15;25(8):2442-2449. doi: 10.1158/1078-0432.CCR-18-2652. Epub 2019 Jan 7.

PMID:
30617133
14.

Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.

Hellerstedt BA, Vogelzang NJ, Kluger HM, Yasenchak CA, Aftab DT, Ramies DA, Gordon MS, Lara P Jr.

Clin Lung Cancer. 2019 Mar;20(2):74-81.e1. doi: 10.1016/j.cllc.2018.10.006. Epub 2018 Oct 24.

15.

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.

Miller NJ, Church CD, Fling SP, Kulikauskas R, Ramchurren N, Shinohara MM, Kluger HM, Bhatia S, Lundgren L, Cheever MA, Topalian SL, Nghiem P.

J Immunother Cancer. 2018 Nov 27;6(1):131. doi: 10.1186/s40425-018-0450-7.

16.

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB.

J Clin Oncol. 2019 Jan 1;37(1):52-60. doi: 10.1200/JCO.18.00204. Epub 2018 Nov 8.

PMID:
30407895
17.

Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.

Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS.

J Am Acad Dermatol. 2019 Apr;80(4):990-997. doi: 10.1016/j.jaad.2018.10.062. Epub 2018 Nov 3.

PMID:
30399387
18.

Anti-PD-1 Therapy-Associated Perforating Colitis.

Celli R, Kluger HM, Zhang X.

Case Rep Gastrointest Med. 2018 May 31;2018:3406437. doi: 10.1155/2018/3406437. eCollection 2018.

19.

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC.

Diabetes. 2018 Aug;67(8):1471-1480. doi: 10.2337/dbi18-0002. Epub 2018 Jun 24. Review.

20.

Genomic Heterogeneity and the Small Renal Mass.

Ueno D, Xie Z, Boeke M, Syed J, Nguyen KA, McGillivray P, Adeniran A, Humphrey P, Dancik GM, Kluger Y, Liu Z, Kluger H, Shuch B.

Clin Cancer Res. 2018 Sep 1;24(17):4137-4144. doi: 10.1158/1078-0432.CCR-18-0214. Epub 2018 May 14.

PMID:
29760223
21.

Early B cell changes predict autoimmunity following combination immune checkpoint blockade.

Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM.

J Clin Invest. 2018 Feb 1;128(2):715-720. doi: 10.1172/JCI96798. Epub 2018 Jan 8.

22.

SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.

Tamiya H, Kim H, Klymenko O, Kim H, Feng Y, Zhang T, Han JY, Murao A, Snipas SJ, Jilaveanu L, Brown K, Kluger H, Zhang H, Iwai K, Ronai ZA.

J Clin Invest. 2018 Jan 2;128(1):517-530. doi: 10.1172/JCI95410. Epub 2017 Dec 11.

23.

A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.

Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H.

Cancer Immunol Res. 2018 Jan;6(1):79-86. doi: 10.1158/2326-6066.CIR-17-0412. Epub 2017 Dec 5.

24.

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.

Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas NB, Kluger HM.

Clin Cancer Res. 2018 Jan 1;24(1):217-223. doi: 10.1158/1078-0432.CCR-17-1555. Epub 2017 Oct 24.

25.

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, Wolchok JD, Sznol M.

J Clin Oncol. 2018 Feb 1;36(4):391-398. doi: 10.1200/JCO.2017.72.2850. Epub 2017 Oct 17.

26.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS.

J Immunother. 2017 Nov/Dec;40(9):334-340. doi: 10.1097/CJI.0000000000000186.

27.

Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.

An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J.

Radiother Oncol. 2017 Oct;125(1):80-88. doi: 10.1016/j.radonc.2017.08.009. Epub 2017 Sep 12.

PMID:
28916225
28.

Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.

Reddy SB, Possick JD, Kluger HM, Galan A, Han D.

J Immunother. 2017 Oct;40(8):307-311. doi: 10.1097/CJI.0000000000000181.

PMID:
28737620
29.

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I.

Ann Oncol. 2017 Aug 1;28(8):1988-1995. doi: 10.1093/annonc/mdx190.

30.

Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.

Smithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, Neumeister VM, Sznol M, Kluger HM, Rimm DL.

J Immunother Cancer. 2017 Mar 21;5:25. doi: 10.1186/s40425-017-0229-2. eCollection 2017.

31.

Comparing available criteria for measuring brain metastasis response to immunotherapy.

Qian JM, Mahajan A, Yu JB, Tsiouris AJ, Goldberg SB, Kluger HM, Chiang VLS.

J Neurooncol. 2017 May;132(3):479-485. doi: 10.1007/s11060-017-2398-8. Epub 2017 Mar 8.

PMID:
28275886
32.

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.

Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB.

Clin Cancer Res. 2017 Aug 1;23(15):4270-4279. doi: 10.1158/1078-0432.CCR-16-3146. Epub 2017 Feb 21.

33.

From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma.

Weiss SA, Kluger HM.

Cancer J. 2017 Jan/Feb;23(1):1-2. doi: 10.1097/PPO.0000000000000244. No abstract available.

34.

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.

Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI.

Br J Cancer. 2017 Feb 14;116(4):432-440. doi: 10.1038/bjc.2016.419. Epub 2017 Jan 19.

35.

Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.

Boddupalli CS, Bar N, Kadaveru K, Krauthammer M, Pornputtapong N, Mai Z, Ariyan S, Narayan D, Kluger H, Deng Y, Verma R, Das R, Bacchiocchi A, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM.

JCI Insight. 2016 Dec 22;1(21):e88955. doi: 10.1172/jci.insight.88955.

36.

The Treatment of Melanoma Brain Metastases.

Kibbi N, Kluger H.

Curr Oncol Rep. 2016 Dec;18(12):73. Review.

PMID:
27822695
37.

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.

Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M.

Clin Cancer Res. 2016 Nov 15;22(22):5461-5471. doi: 10.1158/1078-0432.CCR-15-2839. Epub 2016 May 11.

38.

Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642. doi: 10.1111/pcmr.12538. Epub 2016 Oct 22. Review.

39.

Evolving Immunotherapy Approaches for Renal Cell Carcinoma.

Curtis SA, Cohen JV, Kluger HM.

Curr Oncol Rep. 2016 Sep;18(9):57. doi: 10.1007/s11912-016-0542-9. Review.

PMID:
27475806
40.

MET Inhibition in Clear Cell Renal Cell Carcinoma.

Xie Z, Lee YH, Boeke M, Jilaveanu LB, Liu Z, Bottaro DP, Kluger HM, Shuch B.

J Cancer. 2016 Jun 18;7(10):1205-14. doi: 10.7150/jca.14604. eCollection 2016.

41.

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.

Qian JM, Yu JB, Kluger HM, Chiang VL.

Cancer. 2016 Oct;122(19):3051-8. doi: 10.1002/cncr.30138. Epub 2016 Jun 10.

42.

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM.

Lancet Oncol. 2016 Jul;17(7):976-983. doi: 10.1016/S1470-2045(16)30053-5. Epub 2016 Jun 3.

43.

Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism.

Hollander L, Guo X, Velazquez H, Chang J, Safirstein R, Kluger H, Cha C, Desir GV.

Cancer Res. 2016 Jul 1;76(13):3884-94. doi: 10.1158/0008-5472.CAN-15-1524. Epub 2016 May 9.

44.

Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.

Li J, Kluger H, Devine L, Lee JJ, Kelly WK, Rink L, Saif MW.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1193-200. doi: 10.1007/s00280-016-3033-7. Epub 2016 Apr 21.

PMID:
27103123
45.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA.

N Engl J Med. 2016 Jun 30;374(26):2542-52. doi: 10.1056/NEJMoa1603702. Epub 2016 Apr 19.

46.

Systemic Immunotherapy for the Treatment of Brain Metastases.

Cohen JV, Kluger HM.

Front Oncol. 2016 Mar 9;6:49. doi: 10.3389/fonc.2016.00049. eCollection 2016. Review. No abstract available.

47.

Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases.

Alomari AK, Cohen J, Vortmeyer AO, Chiang A, Gettinger S, Goldberg S, Kluger HM, Chiang VL.

Cancer Immunol Res. 2016 Jun;4(6):481-7. doi: 10.1158/2326-6066.CIR-15-0238. Epub 2016 Mar 18.

48.

Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2170-5. doi: 10.1073/pnas.1525735113. Epub 2016 Feb 10.

49.

Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery.

Rutter CE, Johung KL, Yao X, Lu AY, Jilaveanu LB, Yu JB, Contessa JN, Kluger HM, Chiang VLS, Bindra RS.

J Radiosurg SBRT. 2016;4(2):97-106.

50.

Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, Chiang VL, Kluger HM.

Cancer Immunol Res. 2016 Mar;4(3):179-82. doi: 10.1158/2326-6066.CIR-15-0160. Epub 2015 Dec 23.

Supplemental Content

Loading ...
Support Center